PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
PET/computed tomography evaluation of neuroendocrine tumors is gaining prominence with the availability of novel pet radiotracers, such as (18)F-DOPA and gallium 68 somatostatin peptide derivatives. These tumors have unique properties and hence the basis of use of these new radiotracers. Prominent centers worldwide have reported the usefulness of these PET tracers in diagnosis and clinical decision making. Portability of 68Ge/68Ga generators has also helped in more widespread use of these somatostatin peptide derivatives as PET radiotracers. This article reviews established and potential roles of these novel PET radiotracers in diagnosis, management, and prognosis of neuroendocrine tumors.